Pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us Pharmalicensing.com: Industry news http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Novartis launches Prevacid Basel, November 12, 2009 - Novartis announced the availability of Prevacid http://pharmalicensing.com/redirs/news_rss//public/news/view/499908/6/0/novartis-launches-prevacid http://pharmalicensing.com/redirs/news_rss//public/news/view/499908/6/0/novartis-launches-prevacid Covidien Introduces First FDA-Approved Spine Sealant NORTH HAVEN, Conn.--Nov. 11, 2009-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of DuraSeal(TM) spine sealant, the first product approved by the... http://pharmalicensing.com/redirs/news_rss//public/news/view/499716/6/0/covidien-introduces-first-fda-approved-spine-sealant http://pharmalicensing.com/redirs/news_rss//public/news/view/499716/6/0/covidien-introduces-first-fda-approved-spine-sealant The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma Milan (Italy), 11 November 2009 - MolMed S.p.A. (Milan:MLM) announces that the European Commission has granted Orphan Drug designation for MolMed's investigational new antitumour therapeutic drug... http://pharmalicensing.com/redirs/news_rss//public/news/view/499722/6/0/the-european-commission-grants-orphan-drug-designation-for-ngr-htnf-in-the-treatment-of-hepatocellular-carcinoma http://pharmalicensing.com/redirs/news_rss//public/news/view/499722/6/0/the-european-commission-grants-orphan-drug-designation-for-ngr-htnf-in-the-treatment-of-hepatocellular-carcinoma Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product EXTON, Pa., November 11, 2009 -- Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical... http://pharmalicensing.com/redirs/news_rss//public/news/view/499750/6/0/kensey-nash-receives-fda-510-k-clearance-for-porcine-dermis-biologic-product http://pharmalicensing.com/redirs/news_rss//public/news/view/499750/6/0/kensey-nash-receives-fda-510-k-clearance-for-porcine-dermis-biologic-product Pandemic 2009 Influenza Update: US FDA approves GSK's pandemic H1N1 vaccine 10 November 2009, London UK & Philadelphia US -- GlaxoSmithKline (GSK) today announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA)... http://pharmalicensing.com/redirs/news_rss//public/news/view/499780/6/0/pandemic-2009-influenza-update-us-fda-approves-gsks-pandemic-h1n1-vaccine http://pharmalicensing.com/redirs/news_rss//public/news/view/499780/6/0/pandemic-2009-influenza-update-us-fda-approves-gsks-pandemic-h1n1-vaccine IRONWOOD AND ASTELLAS ANNOUNCE JAPAN LICENSING AGREEMENT FOR LINACLOTIDE CAMBRIDGE, Mass. and TOKYO, Japan, November 10, 2009-- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive... http://pharmalicensing.com/redirs/news_rss//public/news/view/499593/6/0/ironwood-and-astellas-announce-japan-licensing-agreement-for-linaclotide http://pharmalicensing.com/redirs/news_rss//public/news/view/499593/6/0/ironwood-and-astellas-announce-japan-licensing-agreement-for-linaclotide Merit Medical Announces 510(K) Clearance for the Merit Laureate(TM) Hydrophilic Guide Wire SOUTH JORDAN, Utah, November 10, 2009 -- Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic... http://pharmalicensing.com/redirs/news_rss//public/news/view/499594/6/0/merit-medical-announces-510-k-clearance-for-the-merit-laureate-tm-hydrophilic-guide-wire http://pharmalicensing.com/redirs/news_rss//public/news/view/499594/6/0/merit-medical-announces-510-k-clearance-for-the-merit-laureate-tm-hydrophilic-guide-wire Lonza successfully develops a manufacturing process for ArzerraTM (ofatumumab), a new biopharmaceutical from GSK and Genmab Basel, Switzerland, 10 November 2009 - Lonza announces that GlaxoSmithKline (GSK) and Genmab's antibody ArzerraTM, which has just been approved for use in patients with chronic lymphocytic leukemia... http://pharmalicensing.com/redirs/news_rss//public/news/view/499602/6/0/lonza-successfully-develops-a-manufacturing-process-for-arzerratm-ofatumumab-a-new-biopharmaceutical-from-gsk-and-genmab http://pharmalicensing.com/redirs/news_rss//public/news/view/499602/6/0/lonza-successfully-develops-a-manufacturing-process-for-arzerratm-ofatumumab-a-new-biopharmaceutical-from-gsk-and-genmab Teva Receives Favorable Court Decision Regarding Generic Prevacid Jerusalem, Israel, November 10, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Delaware has issued a decision in its... http://pharmalicensing.com/redirs/news_rss//public/news/view/499643/6/0/teva-receives-favorable-court-decision-regarding-generic-prevacid http://pharmalicensing.com/redirs/news_rss//public/news/view/499643/6/0/teva-receives-favorable-court-decision-regarding-generic-prevacid Teva Receives Final Approval For Generic Prevacid Jerusalem, Israel, November 10, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's... http://pharmalicensing.com/redirs/news_rss//public/news/view/499645/6/0/teva-receives-final-approval-for-generic-prevacid http://pharmalicensing.com/redirs/news_rss//public/news/view/499645/6/0/teva-receives-final-approval-for-generic-prevacid